MA
MaaT Pharma S.A.
MAAT.PA · PAR
1.01 € -1.94% (-0.02 €)
1M -64.93%
Market Cap 19.0M €
P/E Ratio -
Div. Yield -
ROE 269.86%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
21 /100
Expensive P/S 4.20x
P/B 10.56x
P/E N/A
Growth
78 /100
Growing Rev. growth 46.80%
Book val. growth 59.36%
EPS growth N/A
Profitability
11 /100
Weak Gross margin 30.70%
FCF margin 365.21%
Net margin 686.58%
Quality
1 /100
Poor ROIC 101.22%
Asset turnover 0.10x
ROE 269.86%
Debt
22 /100
High Debt/Equity 9.69x
Int. coverage -26.91x
Current ratio 1.94x
Stability
69 /100
Stable Beta 0.41x
Profitable years 0
Rev. volatility 7.89%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MAAT.PA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Herve Affagard
Employees
56
Headquarters
Lyon
Upcoming events
01 APR
Earnings
Upcoming earnings report